The sterile-compounding suite is the cleanroom-manufacturing core of the hospital pharmacy — a sequence of air-classified rooms where compounded sterile preparations (CSPs) such as IV admixtures, large-volume parenterals, syringes, ophthalmics, and patient-specific TPN are prepared under engineered air quality. It is the single most code-driven, mechanically intensive, and certification-gated space in the pharmacy, and on most projects it sets the pace for pharmacy activation.
This article covers the non-hazardous sterile-compounding suite governed by USP General Chapter <797>: its room program, classification logic, primary engineering controls, and the design and delivery decisions that determine whether it certifies on the first attempt. Hazardous-drug compounding (USP <800> and the negative-pressure C-SCA/containment rooms), the detailed anteroom gowning sequence, the controlled-substance vault, the deep HVAC pressure-cascade engineering, and the certification/environmental-sampling protocol are each covered by their own Articles in this Part; this article references them by name but does not duplicate them.
USP General Chapter <797>, Pharmaceutical Compounding — Sterile Preparations, is published by the United States Pharmacopeia and sets the minimum standards for compounding sterile preparations to protect patients from contamination, endotoxins, and incorrect strength. Although USP is a standards body and not a regulator, <797> becomes enforceable through several channels that converge on every U.S. hospital:
The current <797> framework, after a long revision and appeals process, took effect on November 1, 2023, with USP <800> applicable on the same date. The practical design implication: the suite must be built to a published, inspectable standard, and the Board of Pharmacy / AHJ interpretation for the specific jurisdiction must be confirmed early, because state amendments and design-review expectations vary.
A second practical implication is that <797> distinguishes compounding categories by beyond-use date (BUD) and rigor — broadly Category 1 (shorter BUD, may be prepared in a segregated compounding area), Category 2 (longer BUD, requires the full classified cleanroom suite), and Category 3 (longest BUD, with the most stringent controls, testing, and competency requirements). The owner's intended category — driven by the service model and BUD strategy — is the single biggest determinant of how much cleanroom you build. Design must start from the pharmacy's compounding plan, not from a generic room template.
A full Category 2/3 non-hazardous sterile suite is a nested set of rooms organized so that air cleanliness increases as personnel and materials move toward the point of compounding. The canonical components:
| Space | Typical ISO class (in operation) | Role |
|---|---|---|
| Anteroom | ISO Class 8 (or cleaner) | Gowning, hand hygiene, staging, and the transition/airlock between unclassified space and the buffer room. Pass-throughs move supplies in. |
| Buffer room (cleanroom) | ISO Class 7 | The classified room that houses the primary engineering control(s) for non-hazardous compounding; positive pressure relative to the anteroom. |
| Primary engineering control (PEC) | ISO Class 5 | The direct compounding area — laminar airflow workbench (LAFW), Class II BSC, or compounding aseptic isolator (CAI) — where the CSP is actually prepared. |
| Pass-through / transfer hatch | Matches adjoining classification | Material transfer without breaking the door/pressure regime. Interlocked or non-interlocked per design. |
The defining principle is the classification cascade: ISO Class 8 anteroom → ISO Class 7 buffer → ISO Class 5 inside the PEC, with air moving from cleaner to less-clean spaces. (ISO classes refer to ISO 14644-1 airborne particle limits; ISO 5 is the cleanest of these, ISO 8 the least clean.) The buffer room must be physically separated from the anteroom by a wall and door (a "line of demarcation" alone is not sufficient for the longer-BUD categories), and gowning is completed in the anteroom before entering the buffer room.
For non-hazardous compounding the buffer room runs positive to the anteroom (protecting the product). This is the inverse of the hazardous-drug suite, where the containment room runs negative to protect personnel and the environment — a distinction covered in the USP <800> Article and one of the most important not to confuse during design.
A smaller alternative — the segregated compounding area (SCA), an unclassified space containing only an ISO 5 PEC — is permitted only for limited Category 1 compounding with restricted BUDs. Owners frequently want the SCA to save capital, then discover the BUD limits cannot support their service model. Resolve the category/BUD question before sizing.
Cleanroom finishes exist to make the room cleanable, non-shedding, and crevice-free, and to hold pressure. The recurring requirements: